B2M and neoplasm: They found that the LOH and upstream frameshift mutations in B2M were only extensively present during disease progression (Sade-Feldman et al., 2017), suggesting immunoediting of B2M-mutated tumor subclones has already existed earlier in tumor development, or became dominant under selective pressure applied by ICBs.